MWTx 02
Alternative Names: MWTx-02Latest Information Update: 20 Sep 2022
Price :
$50 *
At a glance
- Originator Mabwell Therapeutics
- Class Antibodies
- Mechanism of Action Complement system protein modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Autoimmune disorders; Idiopathic thrombocytopenic purpura
Most Recent Events
- 20 Sep 2022 Preclinical trials in Autoimmune disorders in USA (Parenteral), prior to September 2022 (Mabwell Therapeutics pipeline, September 2022)
- 20 Sep 2022 Preclinical trials in Idiopathic thrombocytopenic purpura in USA (Parenteral), prior to September 2022 (Mabwell Therapeutics pipeline, September 2022)
- 14 Mar 2022 Early research in Idiopathic thrombocytopenic purpura in USA (Parenteral) (Mabwell Therapeutics pipeline, March 2022)